Reduction of plasma CGRP levels in migraine patients treated with erenumab or galcanezumab

Rev Neurol. 2024 May 16;78(10):293-294. doi: 10.33588/rn.7810.2023317.

[Article in English, Spanish]

Authors

D A García-Estévez^{1

2}, A Juanatey-García¹, J Rodríguez-Garrido¹, N Sabbagh-Casado¹, G Jaime-Sánchez¹, L Blanco-García¹

Affiliations

¹ Complexo Hospitalario Universitario de Ourense, Ourense, España.
² Instituto de Investigaciones Sanitarias Galicia Sur. SERGAS-UVIGO, Vigo, España.

Abstract

Reducción de los niveles plasmáticos de CGRP en pacientes con migraña tratados con erenumab o galcanezumab.

Publication types

Letter

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized* / therapeutic use
Calcitonin Gene-Related Peptide Receptor Antagonists / therapeutic use
Calcitonin Gene-Related Peptide*
Female
Humans
Male
Middle Aged
Migraine Disorders* / blood
Migraine Disorders* / drug therapy